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Buyang Huanwu Decoction (BHD) is a well-known traditional Chinese herbal prescription for treating stroke-induced disability.
The objective of this study was to evaluate the eﬃcacy and safety of BHD for acute ischemic stroke. A systematic literature search
was performed in 6 databases until February 2012. Randomized controlled clinical trials (RCTs) that evaluate eﬃcacy and safety
of BHD for acute ischemic stroke were included. Nineteen RCTs with 1580 individuals were identified. The studies were generally
of low methodological quality. Only one of the trial included death or dependency as a primary outcome measure. Only 4 trials
reported adverse events. Meta-analysis showed the clinical eﬀective rate of neurological deficit improvement favoring BHD when
compared with western conventional medicines (WCM), P < 0.001. There is significant diﬀerence in the neurologic deficit score
between the BHD treatment group and the WCM control group, P < 0.001. In Conclusion, BHD appears to improve neurological
deficit and seems generally safe in patients with acute ischemic stroke. However, the current evidence is insuﬃcient to support
a routine use of BHD for acute ischemic stroke due to the poor methodological quality and lack of adequate safety data of the
included studies. Further rigorously designed trials are required.
1. Introduction
Stroke is one of the major causes of disability and depen-
dence in the world [1], and WHO estimated that it accounts
for 5.7 million deaths worldwide in 2005, which is equivalent
to 9.9% of all deaths [2]. The rates of stroke mortality
and burden vary greatly among countries, but low-income
countries are the most aﬀected [3]. Ischemic stroke was
the most common subtype, accounting for about 80% of
all strokes. However, the optimization of modern clinical
treatment with acute ischemic stroke was only an integrated
and systematic approach with thrombolysis, if indicated, and
aggressive supportive care [4]. Therefore, the rising number
of stroke patients resorts to various kinds of complementary
and/or alternative medicine (CAM) worldwide.
China, as a developing country, has the largest number
of stroke cases in the world because it has a population
of 1.34 billion in 2011. The most appreciable diﬀerence
between China and the Western countries in treating stroke
is the use of Traditional Chinese Medicine (TCM) therapy
including Chinese herbal medicine (CHM), acupuncture,
and other nonmedication therapies [5]. Buyang Huanwu
Decoction(BHD) is a well-known classic TCM herbal pre-
scription for ischemic stroke and has been used for func-
tional recovery of stroke-induced disability for more than
200 years [6]. BHD is composed of seven kinds of Chi-
nese medicine: Huangqi (Radix Astragali seu Hedysari),
Danggui (Radix Angelicae Sinensis), Chishao (Radix Paeo-
niae Rubra), Chuanxiong (Rhizoma Ligustici Chuanxiong),
Honghua (Flos Carthami), Taoren (Semen Persicae), and
Dilong (Pheretima), all of which are recorded in the Chinese
Pharmacopoeia. In modern time, BHD is still widely used
throughout China and elsewhere in the world for the
treatment of ischemic stroke. Experimental studies indicate
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that BHD has neuroprotective and neurogenesis-promoting
eﬀects. Main findings are as the follows: protecting neurons
from ischemic injury [7, 8], promoting the regeneration of
peripheral nerves [9] and diﬀerentiation of neural progenitor
cells [10], improving recovery of neurological function,
reducing infarction volume, stimulating neural proliferation
[11], and repairing the injured blood vessels and lesion
tissues [12]. However, there is still a lack of reliable scientific
evidence for BHD treatment in patients with ischemic stroke.
BHD is commonly used in the acute, recovery, and seque-
lae stages of patients with ischemic stroke in China. However,
the most important period of recovery is at the acute and
subacute stages during the clinical course of ischemic stroke
[13]. In this study, we aimed to evaluate the clinical eﬃcacy
and safety of BHD therapy for patients suﬀering from acute
ischemic stroke within the first seven days of onset.
2. Methods
2.1. Eligibility Criteria
Types of Studies. Randomized controlled clinical trials
(RCTs) that evaluate eﬃcacy and safety of BHD for ischemic
stroke patients were included. Quasi-RCTs were not con-
sidered such as using the admission sequence for treatment
allocation.
Types of Participants. Patients of any gender, age, or race/
ethnicity with ischemic stroke within 7 days of onset were
considered. The ischemic stroke was diagnosed clinically
according to the World Health Organization definition [14]
or the diagnostic criteria issued at the Second and revised at
the Fourth National Cerebrovascular Diseases Conference in
China [15, 16] and approved by CT scan or MRI.
Types of Interventions. The patients of the control groupwere
given western conventional medicines (WCM). WCM refer
to the combination of needed therapies of the following
aspects: (1) general supportive care mainly includes (A)
airway, ventilatory support and supplemental oxygen, (B)
cardiac monitoring and treatment, (C) temperature, (D)
blood pressure, (E) blood sugar, and (F) nutrition; (2) spe-
cialized caremainly includes a variety ofmeasures to improve
cerebral blood circulation (such as antiplatelet agents, anti-
coagulants, fibrinogen-depleting agents, volume expansion,
and vasodilators, except thrombolytic agents) and neuropro-
tective agents; (3) treatment of acute complications mainly
includes (A) brain edema and elevated intracranial pressure,
(B) seizures, (C) dysphagia, (D) pneumonia, (E) voiding
dysfunction and urinary tract infections, and (F) deep vein
thrombosis. The intervention for control group included
only WCM treatments. Studies comparing BHD therapy to
another form of Chinese herbal medicine were excluded. The
patients at the treatment groups were given BHD therapy in
addition to WCM which was similar to the control group.
Modified BHDwas (BHDplus few herbal) also included. The
clinical trials were included regardless of length of treatment
period and dosage of treatment.
Types of Outcome Measures. The primary outcome measures
were death or dependency at the end of followup (at least
3 months). Dependency was defined as need assistance in
activity of daily living, such as the Barthel Index ≤60. The
secondary outcome measures were the neurological deficit
improvement after treatment and adverse events. The scores
of neurological deficit improvement and the eﬀective rate
were both considered in the neurological deficit improve-
ment.
In this paper, the neurologic deficit score criteria were
adopted based on the Modified Edinburgh-Scandinavian
Stroke Scale, a nationwide accepted scoring system recom-
mended at the Second and revised at the Fourth National
Cerebrovascular Diseases Conference in China [17], includ-
ing consciousness, gaze, facial paresis, language, walking
ability, motor function of arms, legs, and hands. The eﬀec-
tive rate was conducted in accordance with the Modified
Edinburgh-Scandinavian Stroke Scale, which classified dis-
ability into five categories as cure (the scores of functional
deficit were decreased up to 91–100%, and disability degree
was at grade 0), significant improvement (the scores of
functional deficit were decreased at 46–90%, and disability
degree was at the grade 1–3), improvement (the scores of
functional deficit were decreased at 18–45%), no improve-
ment (the scores of functional deficit were decreased at about
17%), and deterioration (the scores of functional deficit
were increased over 18%). Moreover, it was dichotomized
as eﬀective (including the categories of cure, significant
improvement, and improvement) and ineﬀective (including
the categories of no improvement and deterioration) [17].
2.2. Information Sources and Search. We searched Cochrane
library; PubMed; EMBASE; China National Knowledge
Infrastructure; VIP Journals Database; Wanfang database
until February 2012. The search terms used were (Bu-
yang Huan-wu decoction OR Bu-yang-Huan-wu decoction)
AND (Ischemic Stroke OR Cerebral infarction OR cerebral
embolism); Chinese Databases were also searched using the
above search terms in Chinese. We hand-searched Chinese
journals that may publish potentially eligible studies and
conference proceedings relevant to this topic. The reference
lists of all relevant articles were searched for further studies.
2.3. Study Selection and Data Collection Process. All articles
were read by two independent reviewers (Hao CZ, Wu F),
who extracted data from the articles according to a stan-
dardized data extraction form, including patients, methods,
interventions, and outcomes. The reasons for the exclusion
of studies were recorded accordingly. For eligible studies, two
review authors (Hao CZ, Wu F) extracted the data indepen-
dently. Disagreements were resolved through consultation
with a third party author (Zheng GQ or Liao WJ).
2.4. Risk of Bias in Individual Studies. The risk of bias
was assessed using the twelve criteria recommended by the
Cochrane Back Review Group [18], and the level of evidence
was assessed by the GRADE system [19–22]. Disagreements
were resolved by discussion between the two reviewers
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database searching
None of additional records
identified through other sources
354 of records screened on
title/abstract
99 of full-text articles assessed for
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19 of studies included in qualitative
synthesis
18 of studies included in
meta-analysis
255 of records excluded
- Studies not reporting clinical
trials
- Case report
- Study lack of comparison group
80 of full-text articles excluded
- Not real RCTs with admission
sequence used for allocation (7)
- Unclear of the onset time (40)
- Not conform to the diagnostic
criteria (21)
ﬃcacy
criteria (9)
- Adopt other Chinese herbal
medicine in the treatment (3)
- Adopt nonstandard e
Figure 1: Flowchart of trials selection process.
(C.-z. Hao, F. Wu), with the opinion of a third party author
(G.-q. Zheng or W.-j. Liao) if necessary.
2.5. Summary Measures and Synthesis of Results. We synthe-
sized the results in a meta-analysis. A fixed-eﬀects model
or random-eﬀect model was used across the trials, and
risk ratios with their 95% confidence intervals (CI) were
calculated for dichotomous data. If continuous data were
available, weighted mean diﬀerence or standardized mean
diﬀerence was to be calculated using RevMan 5.1 software
provided by the Cochrane Collaboration, and Cochrane’s Q-
test. I2 were used to assess heterogeneity. Where possible, we
assessed publication bias using a funnel plot.
3. Results
3.1. Study Selection. On the basis of search strategy, we
identified 354 potentially relevant articles, and 255 articles
were excluded because they were not reporting clinical trials,
case report, or lacking comparison group. Of the remaining
99 articles, 80 were excluded because 7 articles were not real
RCTs with admission sequence used for treatment allocation,
61 with patients who did not meet the criteria of the types of
participants; there are 3 trials used Chinese Herbal Injections
in control group and 9 adopted nonstandard eﬃcacy criteria.
Finally, 19 studies, involving a total of 1580 participants,
met our inclusion criteria [23–41]. The screening process is
summarized in a flow diagram (Figure 1).
3.2. Study Characteristics. The 19 studies included were all
conducted in China and published between 1995 and 2012,
and all of them were performed in a single center. The
sample size was small, with 3 having a size less than 50,
and 11 between 50 and 100, the other 5 between 100 and
200, and none reported sample size estimation. All the
19 RCTs based the diagnosis of acute ischemic stroke on
both clinical examination and CT or MRI. All the 19 RCTs
used BHD combining with conventional western therapy as
the treatment group, and conventional western therapy as
control group. The duration of studies lasted from 10 days
to 30 days. Both clinical eﬀective rate and neurologic deficit
scores were observed in 8 studies, while only clinical eﬀective
rate was observed in 9 studies, only neurologic deficit scores
were observed in 1 studies [28], and one study observed
the ESS neurologic deficit scores [29]. Adverse eﬀects were
reported in 4 studies [29, 32, 38, 39], while the other 15
included trials not mentioning adverse events at all. Key data
are summarized in Table 1.
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Figure 2: Funnel plot of the total eﬀective rate of BHD therapy for
acute ischemic stroke.
3.3. Risk of Bias within Studies. All of the studies were de-
scribed as randomized, but no study reported the method of
random sequences generation. No study mention allocation
concealment. Only one study mentioned single blinding
[39], but not did mentioned either subjects or investigator or
assessor blinding. None of the studies described intention-
to-treat analyses, and no study reported follow-up or drop-
out data. In general, all 19 RCTs showed an unclear risk of
bias based on the Cochrane Risk of Bias tool (Table 2).
Based on GRADE system, the evidence of eﬀective rate
and neurological deficit scores (Modified Edinburgh-Scan-
dinavian Stroke Scale) was level D, while the evidences of
neurological deficit scores (ESS) was level C, and all of them
were weak recommendation (Table 3).
3.4. Results of Individual Studies
3.4.1. Death or Dependency. One study used the Barthel
Index to evaluate the dependency rate [31]. The result
indicated that there was no statistically significant diﬀerence
between the two groups (Peto OR, 0.36; 95% CI, 0.12 to
1.07). Only one trial reported one case of death in the control
group. None of the studies reported the mortality and
dependency at the end of followup (at least three months).
3.4.2. Adverse Events. 4 studies reported that there were no
adverse events [29, 32, 38, 39], while the left 15 studies did
not mention adverse events. However, no life threatening
adverse eﬀects were noted in these studies.
3.5. Synthesis of Results
3.5.1. The Eﬀective Rate of Neurological Deficit Improvement.
17 of the included studies which adopted the eﬀective rate
to assess the clinical improvement were qualified to perform
a meta-analysis, and the random-eﬀect model was used for
statistical analysis because of the heterogeneity (n = 1444,
RR 1.18, 95%CI 1.12 to 1.24, P < 0.001, heterogeneity χ2 =
24.82, P = 0.07, I2 = 36%) favoring BHD (Table 4). The
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Figure 3: Funnel plot of the scores of neurological deficit of BHD
therapy for acute ischemic stroke.
publication bias funnel plot provided evidence of publication
bias (Figure 2).
3.5.2. The Neurologic Deficit Score. 9 studies which used the
neurologic deficit score were qualified to perform a meta
analysis, and the random-eﬀect model was used for statistical
analysis because of the heterogeneity (n = 786, MD −4.65,
95% CI−6.57 to−2.72, P < 0.001, heterogeneity χ2 = 49.62,
P < 0.001, I2 = 84%), and showed the significant diﬀerence
between the BHD therapy group and the control group and
favored BHD (Table 5). We considered high heterogeneity
because of I2 = 84%. Analysis of the study and patient
characteristics suggests the heterogeneity may arise from
diﬀerent course of treatment among the studies (10 days
to 30 days). So we divide the 9 studies into 2 subgroups
according to the course of treatment (15 days, or >15
days). But the results show that heterogeneity does not
decrease (I2 = 87% and I2 = 83%). So we consider that
heterogeneity may arise from other substantial heterogeneity.
The publication bias funnel plot provided evidence of
publication bias (Figure 3). One study [29] adopted the ESS
indicated that the improvement of the neurologic deficit
scores of BHD group was significantly higher than that of
control group (P < 0.01).
4. Discussion
4.1. Summary of Evidence. Nineteen studies with 1580 indi-
viduals suﬀering from acute ischemic stroke were selected
out for this systematic review on the mortality and depen-
dency, clinical eﬃcacy, and safety of BHD treatment for acute
ischemic stroke. The main finding of this review was that
BHD therapy could improve the neurological deficit of acute
ischemic stroke. However, a clinical recommendation cannot
be warranted because of the generally low methodological
quality of the included studies. Another finding suggested
that there was no evidence available about the eﬀect of
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Table 2: The methodological quality of the included trials.
First author year A B C D E F G H I J K L
Zhang 2010 [12] ? ? − − ? − − ? + + + +
Wu 2011 [23] ? ? − − ? − − ? + + + +
Zhang 2004 [24] ? ? − − ? − − ? + + + +
Guo 2009 [25] ? ? − − ? − − ? + + + +
Jia 2010 [26] ? ? − − ? − − ? + + + +
Fang 2005 [27] ? ? − − ? − − ? + + + +
Zhang 2012 [28] ? ? − − ? − − ? + + + +
Li 2011 [29] ? ? − − ? − − ? + + + +
Kang 2006 [30] ? ? − − ? − − ? + + + +
Lin 2008 [31] ? ? − − ? − − ? + + + +
Chen 2007 [32] ? ? − − ? − − ? + + + +
Yan 2004 [33] ? ? − − ? − − ? + + + +
Cui 2005 [34] ? ? − − ? − − ? + + + +
Liu 2010 [35] ? ? − − ? − − ? + + + +
Shi 1995 [36] ? ? − − ? − − ? + + + +
Run 2001 [37] ? ? − − ? − − ? + + + +
Wang 2005 [38] ? ? − − ? − − ? + + + +
Lv 2009 [39] ? ? ? ? ? − − ? + + + +
Zheng 2004 [40] ? ? − − ? − − ? + + + +
A: adequate sequence generation; B: concealment of allocation; C: blinding (patient); D: blinding (investigator); E: blinding (assessor); F: incomplete outcome
data addressed (ITT analysis); G: incomplete outcome data addressed (dropouts); H: free of selective reporting; I: similarity at baseline; J: cointerventions
constant; K: compliance acceptable; L: timing outcome assessments. +Yes, −No, ?Unclear.
BHD therapy on the primary outcomes because none of the
studies included the rates of death or dependency at the end
of followup (at least 3 months). At last, BHD therapy was
generally safe for acute ischemic stroke. However, adverse
reactions should be rigorously investigated to assess the
safety because only 21.1% studies mentioned the safety of
BHD therapy.
4.2. Limitations. Firstly, there are also a number of method-
ological limitations in this systematic review. None of the
included trials reported the random method or allocation
concealment, which may produce selection bias. Only one
study mentioned blinding, but did not mention either sub-
jects or investigator or assessor blinding. None of the studies
described intention-to-treat analyses, and no study reported
follow-up or dropout data; all of which are likely to show
exaggerated treatment eﬀects. Moreover, it is well established
that 5 to 6 months after stroke are an appropriate time point
at which to measure neurological and functional outcome,
for spontaneous recovery does not reach a plateau until 5 to
6 months after stroke [42]. But all of the trials evaluated the
eﬃcacy immediately after completing the treatment, and the
period of followup was not long enough to evaluate the long-
term eﬀect of BHD treatment.
Secondly, the testified intervention should be compared
with placebo-controlled or current “gold standard treat-
ment” rather than randomly chosen unproved treatment
[42]. All studies included in this review used an “A + B
versus B” design where patients were randomized to receive a
BHD adjuvant therapy plus WCM versus WCM. None of the
trials chose any sham or placebo as control, and the WCMs
were not “gold standard treatment” but randomly chosen
unproved treatment, which raises potential to bias.
Thirdly, the outcome measure of most of the trials was
defined as an “eﬀective rate,” the validity and reliability of
which were uncertain in assessing the outcome. The primary
outcome measure should be focused on the level of activities
rather than a vague eﬀective rate [42]. The fatality rate in
the primary trials was too low to be reliable, because only
1 trial reported the occurrence of one case death. Although
there are several possibilities [43], such as a truly low case
fatality rate for ischemic stroke in China, the patients with
severe stroke were not sent to hospitals (admission bias), a
reluctance of researchers to include severe strokes in research
studies (selection bias) or failure to report major outcome
events (reporting bias), and only trials with low mortality
rates submitted their results for publication (publication
bias), but the most probable attribution was lack of true
randomization.
Lastly, we made an eﬀort to identify all relevant studies,
including those in the West and the East. However, all the
studies met the criteria were from China, and this may limit
the generalizability of the findings.
5. Conclusion
This systematic review provides suggestive evidence for the
eﬀectiveness and safety of BHD adjuvant therapy to disability
improvement after acute ischemic stroke. However, a clinical
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Table 4: Meta-analyses of the total eﬀective rate of BHD therapy for acute ischemic stroke.
Study or subgroup
Experimental Control
Weight
Risk ratio Risk ratio
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI
Chen, 2007 [32] 28 32 21 32 3.0% 1.33 [1.00, 1.77]
Favours
control
Favours
experiment
0.5 0.7 1.51 2
Cui et al., 2005 [34] 49 50 25 30 6.6% 1.18 [1.00, 1.39]
Fang et al., 2005 [27] 58 65 47 72 5.5% 1.37 [1.13, 1.65]
Guo, 2009 [25] 56 57 27 30 9.1% 1.09 [0.96, 1.24]
Jia et al., 2010 [26] 30 32 21 28 4.1% 1.25 [0.99, 1.58]
Kang, 2006 [30] 35 36 35 38 10.4% 1.06 [0.95, 1.18]
Lin, 2008 [31] 30 32 22 30 4.0% 1.28 [1.01, 1.61]
Liu, 2010 [35] 52 55 40 55 6.2% 1.30 [1.09, 1.55]
Lv, 2009 [39] 33 35 30 35 7.0% 1.10 [0.94, 1.29]
Run, 2001 [37] 21 24 14 24 1.8% 1.50 [1.04, 2.17]
Shi and Zhang, 1995
[36]
17 21 12 20 1.5% 1.35 [0.89, 2.04]
Wang and Yu, 2005 [38] 62 64 55 64 10.4% 1.13 [1.01, 1.26]
Wu and Luo, 2011 [23] 33 35 29 35 6.3% 1.14 [0.96, 1.35]
Yan and Mei, 2004 [33] 55 60 52 60 9.1% 1.06 [0.93, 1.20]
Zhang, 2004 [24] 36 40 25 40 3.4% 1.44 [1.11, 1.87]
Zhang et al., 2010 [12] 77 82 67 82 9.7% 1.15 [1.02, 1.29]
Zheng et al., 2004 [40] 24 27 13 22 1.8% 1.50 [1.04, 2.18]
Total (95% CI) 747 697 100.0% 1.18 [1.12, 1.24]
Total events 696 535
Heterogeneity: Tau2 = 0.00; Chi2 = 24.82, df = 16 (P = 0.07); I2 = 36%
Test for overall eﬀect: Z = 6.02 (P < 0.00001)
Table 5: Meta-analyses of the scores of neurological deficit of BHD therapy for acute ischemic stroke.
Study or subgroup
Experimental Control
Weight
Mean diﬀerence Mean diﬀerence
Events SD Total Events SD Total IV, random, 95% CI IV, random, 95% CI
Chen, 2007 [32] 13.55 9.22 32 11.9 8.89 32 8.3% 1.65 [−2.79, 6.09]
−10 −5 0 5 10
Favours
control
Favours
experiment
Guo, 2009 [25] 5.28 7.51 57 11.25 7.59 30 10.2% −5.97 [−9.31, −2.63]
Kang, 2006 [30] 5.14 1.86 36 8.22 2.04 38 14.3% −3.08 [−3.97, −2.19]
Lv, 2009 [39] 12.86 7.92 35 19.67 8.36 35 9.3% −6.81 [−10.63, −2.99]
Wang and Yu, 2005 [38] 8.82 7.92 64 18.5 8.82 64 11.0% −9.68 [−12.58, −6.78]
Zhang, 2004 [24] 7.12 7.45 40 14.56 7.4 40 10.4% −7.44 [−10.69, −4.19]
Zhang et al., 2010 [12] 12.02 6.39 82 14.39 7.29 82 12.6% −2.37 [−4.47, −0.27]
Zhang et al., 2012 [28] 11.26 2.56 36 17.84 3.86 34 13.5% −6.58 [−8.12, −5.04]
Zheng et al., 2004 [40] 18.08 5.16 27 18.77 6.24 22 10.4% −0.69 [−3.94, 2.56]
Total (95% CI) 409 377 100.0% −4.65 [−6.57,−2.72]
Heterogeneity: Tau2 = 6.54; Chi2 = 49.62, df = 8 (P < 0.00001); I2 = 84%
Test for overall eﬀect: Z = 4.73 (P < 0.00001)
recommendation cannot be warranted because of the gener-
ally unclear methodological quality of the included studies.
We did not find suﬃcient evidence on the primary measure
of eﬃcacy to support the routine use of BHD therapy for
ischemic stroke. BHD therapy may have beneficial eﬀects
on neurological impairment for ischemic stroke, but this
eﬃcacy needs to be further confirmed by methodologically
rigorous trials. Therefore, further RCTs with adequate con-
cealment of allocation, double-blinding, placebo-controlled,
and long-term followup are needed and should be reported
in detail according to the consolidated standards of reporting
trials (CONSORT) 2010 statement [44].
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